z-logo
Premium
Uroplakin II outperforms uroplakin III in diagnostically challenging settings
Author(s) -
Smith Steven C,
Mohanty Sambit K,
Kunju Lakshmi P,
Chang Elena,
Chung Fai,
Carvalho Jason C,
Paner Gladel P,
Hansel Donna E,
Luthringer Daniel J,
PeraltaVentrurina Mariza N,
Amin Mahul B
Publication year - 2014
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12360
Subject(s) - staining , medicine , pathology , antibody , carcinoma , immunohistochemistry , tissue microarray , head and neck , immunology , surgery
Aims We performed a head‐to‐head comparison of an antibody against uroplakin III ( UP 3) and a new uroplakin II ( UP 2) antibody that remains untested in diagnostically challenging settings. Methods and results We immunostained high‐grade bladder neck carcinomas ( n  =   35), high‐grade upper tract urothelial carcinomas ( UC ) and renal carcinomas ( n  =   85), metastases of UC ( n =  30) and a multicancer tissue microarray ( n  =   88) for UP 3 and UP 2, and scored staining intensity and proportion. UP 3 showed membranous plaque‐like expression, while UP 2 staining showed both membranous and cytoplasmic positivity. Significantly greater intensity ( P  =   0.003) and proportion ( P  =   0.03) of staining was noted for UP 2 among bladder neck lesions, with UP 2 staining showing greater sensitivity (63% versus 19%) and similar specificity (95% versus 100%) for UC over prostate carcinoma ( P  =   0.02). Among upper tract lesions, UP 2 staining showed greater intensity and proportion than UP 3 (both P  < 0.001), including improved sensitivity (68% versus 23%) and equal specificity (both 100%) for UC ( P  =   0.006). Among UC metastases, UP 2 staining showed greater intensity and proportion (both P  <   0.001) with higher sensitivity (73% versus 37%, respectively, P  =   0.001). Of 88 additional cases tested, no non‐urothelial cases stained for either UP . Conclusions The UP 2 antibody outperforms the UP 3 antibody, including in diagnostically challenging settings, and is a useful addition to the armamentarium of biomarkers for UC .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here